Competing Securities Class Actions Target Agilon Health Over 2025 Guidance

Overview

• Multiple shareholder-rights firms report filing or soliciting participation in federal class actions for Agilon investors who bought shares between late February and August 4, 2025.
• Complaints contend the company issued unattainable 2025 guidance and overstated the near‑term financial impact of its risk‑reduction “strategic actions.”
• At least one case cites alleged violations of Sections 10(b) and 20(a) of the Exchange Act and SEC Rule 10b‑5.
• The suits center on August 4, 2025 disclosures that CEO Steven Sell had stepped down and that full‑year 2025 guidance was suspended, after which the stock fell about 51.5% to $0.88 on August 5.
• No class has been certified, and law firms are inviting investors to contact them as courts consider consolidation and lead‑plaintiff motions.